PTG-300 in Patients With Polycythemia Vera and Elevated Hematocrit
Status:
Active, not recruiting
Trial end date:
2023-04-30
Target enrollment:
Participant gender:
Summary
This is an open label, single arm trial of PTG-300 in subjects with PV who are newly
diagnosed or for whom current therapy is not sufficient to control their hematocrit and have
hematocrit >48% prior to dosing. The PTG-300 dose and schedule may be adjusted every 2 to 4
weeks to maintain hematocrit <45% with a target of <43%. Subjects may receive PTG-300
treatment for up to 52 weeks.